Trials / Completed
CompletedNCT05064345
A Study to Evaluate HB0034 in Healthy Adult Participants
A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose.
Detailed description
This is a first-in-human (FIH) study of HB0034 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0034.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB0034 | Recombinant Humanized Anti-IL-36R Monoclonal antibody |
| DRUG | Placebo | Palcebo |
Timeline
- Start date
- 2021-12-03
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2021-10-01
- Last updated
- 2022-09-14
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT05064345. Inclusion in this directory is not an endorsement.